Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing

Journal of Experimental Medicine

Volumn 213, Issue 10, 2016, Pages 2065-2080

  Tagawa, Takanobu ^a,b   Albanese, Manuel ^a,b   Bouvet, Mickaël ^a,b   Moosmann, Andreas ^a,b   Mautner, Josef ^a,b,c   Heissmeyer, Vigo ^a,d   Zielinski, Christina ^c   Lutter, Dominik ^a   Hoser, Jonathan ^a   Hastreiter, Maximilian ^a   Hayes, Mitch ^e   Sugden, Bill ^e   Hammerschmidt, Wolfgang ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b German Center for Infection Research   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HLA ANTIGEN CLASS 2; INTERLEUKIN 12; MICRORNA; VIRUS RNA; AUTACOID; CELL SURFACE RECEPTOR; CYTOKINE; PEPTIDE;

ADENOID; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE EVASION; IMMUNOGENICITY; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY CELL; PRIORITY JOURNAL; PROTEIN PROCESSING; RAJI CELL LINE; TH1 CELL; ANTIGEN PRESENTATION; CELL DEATH; CELL DIFFERENTIATION; CELL MEMBRANE; CYTOLOGY; GENETICS; IMMUNITY; IMMUNOLOGY; LYSOSOME; METABOLISM; SPECIES DIFFERENCE; VIROLOGY;

ANTIGEN PRESENTATION; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELL DIFFERENTIATION; CELL MEMBRANE; CYTOKINES; HEK293 CELLS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY; INFLAMMATION MEDIATORS; INTERLEUKIN-12; LYSOSOMES; MICRORNAS; PEPTIDES; RECEPTORS, CELL SURFACE; SPECIES SPECIFICITY; TH1 CELLS;

EID: 84991588443     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20160248     Document Type: Article

References (62)

1. Adhikary, D., U. Behrends, A. Moosmann, K. Witter, G.W. Bornkamm, and J. Mautner. 2006. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J. Exp. Med. 203:995-1006. http://dx.doi.org/10.1084/jem.20051287
2. Adhikary, D., U. Behrends, H. Boerschmann, A. Pfünder, S. Burdach, A. Moosmann, K. Witter, G.W. Bornkamm, and J. Mautner. 2007. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. PLoS One. 2:e583. http://dx.doi.org/10.1371/journal.pone.0000583
3. Bartel, D.P. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281-297. http://dx.doi.org/10.1016/S0092-8674(04)00045-5
4. Bartel, D.P. 2009. MicroRNAs: target recognition and regulatory functions. Cell. 136:215-233. http://dx.doi.org/10.1016/j.cell.2009.01.002
5. Barth, S., G. Meister, and F.A. Grässer. 2011. EBV-encoded miRNAs. Biochim. Biophys. Acta. 1809:631-640. http://dx.doi.org/10.1016/j.bbagrm.2011.05.010
6. Blum, J.S., P.A. Wearsch, and P. Cresswell. 2013. Pathways of antigen processing. Annu. Rev. Immunol. 31:443-473. http://dx.doi.org/10.1146/annurev-immunol-032712-095910
7. Boss, I.W., and R. Renne. 2011. Viral miRNAs and immune evasion. Biochim. Biophys. Acta. 1809:708-714. http://dx.doi.org/10.1016/j.bbagrm.2011.06.012
8. Cai, X., A. Schäfer, S. Lu, J.P. Bilello, R.C. Desrosiers, R. Edwards, N. Raab-Traub, and B.R. Cullen. 2006. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog. 2:e23. http://dx.doi.org/10.1371/journal.ppat.0020023
9. Curtsinger, J.M., and M.F. Mescher. 2010. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 22:333-340. http://dx.doi.org/10.1016/j.coi.2010.02.013
10. Dobin, A., C.A. Davis, F. Schlesinger, J. Drenkow, C. Zaleski, S. Jha, P. Batut, M. Chaisson, and T.R. Gingeras. 2013. STAR: ultrafast universal RNAseq aligner. Bioinformatics. 29:15-21. http://dx.doi.org/10.1093/bioinformatics/bts635
11. Dölken, L., G. Malterer, F. Erhard, S. Kothe, C.C. Friedel, G. Suffert, L. Marcinowski, N. Motsch, S. Barth, M. Beitzinger, et al. 2010. Systematic analysis of viral and cellular microRNA targets in cells latently infected with human γ-herpesviruses by RISC immunoprecipitation assay. Cell Host Microbe. 7:324-334. http://dx.doi.org/10.1016/j.chom.2010.03.008
12. Erhard, F., L. Dölken, L. Jaskiewicz, and R. Zimmer. 2013. PARma: identification of microRNA target sites in AGO-PAR-CLIP data. Genome Biol. 14:R79. http://dx.doi.org/10.1186/gb-2013-14-7-r79
13. Feederle, R., J. Haar, K. Bernhardt, S.D. Linnstaedt, H. Bannert, H. Lips, B.R. Cullen, and H.-J. Delecluse. 2011a. The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes. J. Virol. 85:9801-9810. http://dx.doi.org/10.1128/JVI.05100-11
14. Feederle, R., S.D. Linnstaedt, H. Bannert, H. Lips, M. Bencun, B.R. Cullen, and H.-J. Delecluse. 2011b. A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. PLoS Pathog. 7:e1001294. http://dx.doi.org/10.1371/journal.ppat.1001294
15. Garcia, D.M., D. Baek, C. Shin, G.W. Bell, A. Grimson, and D.P. Bartel. 2011. Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat. Struct. Mol. Biol. 18:1139-1146. http://dx.doi.org/10.1038/nsmb.2115
16. Gottschalk, S., C.M. Rooney, and H.E. Heslop. 2005. Post-transplant lymphoproliferative disorders. Annu. Rev. Med. 56:29-44. http://dx.doi.org/10.1146/annurev.med.56.082103.104727
17. Gottwein, E., D.L. Corcoran, N. Mukherjee, R.L. Skalsky, M. Hafner, J.D. Nusbaum, P. Shamulailatpam, C.L. Love, S.S. Dave, T. Tuschl, et al. 2011. Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. Cell Host Microbe. 10:515-526. http://dx.doi.org/10.1016/j.chom.2011.09.012
18. Grundhoff, A., and C.S. Sullivan. 2011. Virus-encoded microRNAs. Virology. 411:325-343. http://dx.doi.org/10.1016/j.virol.2011.01.002
19. Haneklaus, M., M. Gerlic, M. Kurowska-Stolarska, A.-A. Rainey, D. Pich, I.B. McInnes, W. Hammerschmidt, L.A.J. O'Neill, and S.L. Masters. 2012. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1β production. J. Immunol. 189:3795-3799. http://dx.doi.org/10.4049/jimmunol.1200312
20. Haque, T., G.M. Wilkie, M.M. Jones, C.D. Higgins, G. Urquhart, P. Wingate, D. Burns, K. McAulay, M. Turner, C. Bellamy, et al. 2007. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 110:1123-1131. http://dx.doi.org/10.1182/blood-2006-12-063008
21. Hislop, A.D., N.E. Annels, N.H. Gudgeon, A.M. Leese, and A.B. Rickinson. 2002. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J. Exp. Med. 195:893-905. http://dx.doi.org/10.1084/jem.20011692
22. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. 2010. IARC monographs on the evaluation of carcinogenic risks to humans. Ingested nitrate and nitrite, and cyanobacterial peptide toxins. IARC Monogr. Eval. Carcinog. Risks Hum. 94:v-vii: 1-412
23. Icheva, V., S. Kayser, D. Wolff, S. Tuve, C. Kyzirakos, W. Bethge, J. Greil, M.H. Albert, W. Schwinger, M. Nathrath, et al. 2013. Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J. Clin. Oncol. 31:39-48. http://dx.doi.org/10.1200/JCO.2011.39.8495
24. Iskra, S., M. Kalla, H.J. Delecluse, W. Hammerschmidt, and A. Moosmann. 2010. Toll-like receptor agonists synergistically increase proliferation and activation of B cells by Epstein-Barr virus. J. Virol. 84:3612-3623. http://dx.doi.org/10.1128/JVI.01400-09
25. Iwakiri, D., L. Zhou, M. Samanta, M. Matsumoto, T. Ebihara, T. Seya, S. Imai, M. Fujieda, K. Kawa, and K. Takada. 2009. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J. Exp. Med. 206:2091-2099. http://dx.doi.org/10.1084/jem.20081761
26. Jochum, S., A. Moosmann, S. Lang, W. Hammerschmidt, and R. Zeidler. 2012. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLoS Pathog. 8:e1002704. http://dx.doi.org/10.1371/journal.ppat.1002704
27. Johannsen, E., M. Luftig, M.R. Chase, S. Weicksel, E. Cahir-McFarland, D. Illanes, D. Sarracino, and E. Kieff. 2004. Proteins of purified Epstein-Barr virus. Proc. Natl. Acad. Sci. USA. 101:16286-16291. http://dx.doi.org/10.1073/pnas.0407320101
28. Kalla, M., and W. Hammerschmidt. 2012. Human B cells on their route to latent infection early but transient expression of lytic genes of Epstein-Barr virus. Eur. J. Cell Biol. 91:65-69. http://dx.doi.org/10.1016/j.ejcb.2011.01.014
29. Kalla, M., A. Schmeinck, M. Bergbauer, D. Pich, and W. Hammerschmidt. 2010. AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc. Natl. Acad. Sci. USA. 107:850-855. http://dx.doi.org/10.1073/pnas.0911948107
30. Kieser, A., and K.R. Sterz. 2015. The Latent Membrane Protein 1 (LMP1). Curr. Top. Microbiol. Immunol. 391:119-149
31. Klinke, O., R. Feederle, and H.-J. Delecluse. 2014. Genetics of Epstein-Barr virus microRNAs. Semin. Cancer Biol. 26:52-59. http://dx.doi.org/10.1016/j.semcancer.2014.02.002
32. Kuzembayeva, M., Y.-F. Chiu, and B. Sugden. 2012. Comparing proteomics and RISC immunoprecipitations to identify targets of Epstein-Barr viral miRNAs. PLoS One. 7:e47409. http://dx.doi.org/10.1371/journal.pone.0047409
33. Lo, A.K.F., K.F. To, K.W. Lo, R.W.-M. Lung, J.W.Y. Hui, G. Liao, and S.D. Hayward. 2007. Modulation of LMP1 protein expression by EBVencoded microRNAs. Proc. Natl. Acad. Sci. USA. 104:16164-16169. http://dx.doi.org/10.1073/pnas.0702896104
34. Long, H.M., A.M. Leese, O.L. Chagoury, S.R. Connerty, J. Quarcoopome, L.L. Quinn, C. Shannon-Lowe, and A.B. Rickinson. 2011. Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition. J. Immunol. 187:92-101. http://dx.doi.org/10.4049/jimmunol.1100590
35. Milosevic, S., U. Behrends, H. Christoph, and J. Mautner. 2005. Direct mapping of MHC class II epitopes. J. Immunol. Methods. 306:28-39. http://dx.doi.org/10.1016/j.jim.2005.07.020
36. Moosmann, A., I. Bigalke, J. Tischer, L. Schirrmann, J. Kasten, S. Tippmer, M. Leeping, D. Prevalsek, G. Jaeger, G. Ledderose, et al. 2010. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood. 115:2960-2970. http://dx.doi.org/10.1182/blood-2009-08-236356
37. Nachmani, D., N. Stern-Ginossar, R. Sarid, and O. Mandelboim. 2009. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe. 5:376-385. http://dx.doi.org/10.1016/j.chom.2009.03.003
38. Nimmerjahn, F., D. Kobelt, A. Steinkasserer, A. Menke, G. Hobom, U. Behrends, G.W. Bornkamm, and J. Mautner. 2003. Efficient generation and expansion of antigen-specific CD4+ T cells by recombinant influenza viruses. Eur. J. Immunol. 33:3331-3341. http://dx.doi.org/10.1002/eji.200324342
39. Qiu, J., K. Cosmopoulos, M. Pegtel, E. Hopmans, P. Murray, J. Middeldorp, M. Shapiro, and D.A. Thorley-Lawson. 2011. A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia. PLoS Pathog. 7:e1002193. http://dx.doi.org/10.1371/journal.ppat.1002193
40. Quinn, L.L., L.R. Williams, C. White, C. Forrest, J. Zuo, and M. Rowe. 2015. The missing link in Epstein-Barr virus immune evasion: the BDLF3 gene induces ubiquitination and downregulation of major histocompatibility complex class I (MHC-I) and MHC-II. J. Virol. 90:356-367. http://dx.doi.org/10.1128/JVI.02183-15
41. Rancan, C., L. Schirrmann, C. Hüls, R. Zeidler, and A. Moosmann. 2015. Latent membrane protein LMP2A impairs recognition of EBV-infected cells by CD8+ T cells. PLoS Pathog. 11:e1004906. http://dx.doi.org/10.1371/journal.ppat.1004906
42. Rehmsmeier, M., P. Steffen, M. Höchsmann, and R. Giegerich. 2004. Fast and effective prediction of microRNA/target duplexes. RNA. 10:1507-1517. http://dx.doi.org/10.1261/rna.5248604
43. Ressing, M.E., D. van Leeuwen, F.A.W. Verreck, R. Gomez, B. Heemskerk, M. Toebes, M.M. Mullen, T.S. Jardetzky, R. Longnecker, M.W. Schilham, et al. 2003. Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proc. Natl. Acad. Sci. USA. 100:11583-11588. http://dx.doi.org/10.1073/pnas.2034960100
44. Ressing, M.E., D. Horst, B.D. Griffin, J. Tellam, J. Zuo, R. Khanna, M. Rowe, and E.J.H.J. Wiertz. 2008. Epstein-Barr virus evasion of CD8+ and CD4+ T cell immunity via concerted actions of multiple gene products. Semin. Cancer Biol. 18:397-408. http://dx.doi.org/10.1016/j.semcancer.2008.10.008
45. Ressing, M.E., M. van Gent, A.M. Gram, M.J.G. Hooykaas, S.J. Piersma, and E.J.H.J. Wiertz. 2015. Immune evasion by Epstein-Barr virus. Curr. Top. Microbiol. Immunol. 391:355-381. http://dx.doi.org/10.1007/978-3-319-22834-112
46. Riley, K.J., G.S. Rabinowitz, T.A. Yario, J.M. Luna, R.B. Darnell, and J.A. Steitz. 2012. EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency. EMBO J. 31:2207-2221. http://dx.doi.org/10.1038/emboj.2012.63
47. Rowe, M., B. Glaunsinger, D. van Leeuwen, J. Zuo, D. Sweetman, D. Ganem, J. Middeldorp, E.J.H.J. Wiertz, and M.E. Ressing. 2007. Host shutoffduring productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc. Natl. Acad. Sci. USA. 104:3366-3371. http://dx.doi.org/10.1073/pnas.0611128104
48. Samanta, M., D. Iwakiri, T. Kanda, T. Imaizumi, and K. Takada. 2006. EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. EMBO J. 25:4207-4214. http://dx.doi.org/10.1038/sj.emboj.7601314
49. Seto, E., A. Moosmann, S. Grömminger, N. Walz, A. Grundhoff, and W. Hammerschmidt. 2010. Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog. 6:e1001063. http://dx.doi.org/10.1371/journal.ppat.1001063
50. Skalsky, R.L., and B.R. Cullen. 2010. Viruses, microRNAs, and host interactions. Annu. Rev. Microbiol. 64:123-141. http://dx.doi.org/10.1146/annurev.micro.112408.134243
51. Skalsky, R.L., D.L. Corcoran, E. Gottwein, C.L. Frank, D. Kang, M. Hafner, J.D. Nusbaum, R. Feederle, H.-J. Delecluse, M.A. Luftig, et al. 2012. The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog. 8:e1002484. http://dx.doi.org/10.1371/journal.ppat.1002484
52. Steinbrück, L., M. Gustems, S. Medele, T.F. Schulz, D. Lutter, and W. Hammerschmidt. 2015. K1 and K15 of Kaposi's sarcoma-associated herpesvirus are partial functional homologues of latent membrane protein 2A of Epstein-Barr virus. J. Virol. 89:7248-7261. http://dx.doi.org/10.1128/JVI.00839-15
53. Szabo, S.J., B.M. Sullivan, S.L. Peng, and L.H. Glimcher. 2003. Molecular mechanisms regulating Th1 immune responses. Annu. Rev. Immunol. 21:713-758. http://dx.doi.org/10.1146/annurev.immunol.21.120601.140942
54. Thorley-Lawson, D.A. 2005. EBV the prototypical human tumor virus just how bad is it? J. Allergy Clin. Immunol. 116:251-261. http://dx.doi.org/10.1016/j.jaci.2005.05.038
55. Vereide, D.T., E. Seto, Y.-F. Chiu, M. Hayes, T. Tagawa, A. Grundhoff, W. Hammerschmidt, and B. Sugden. 2014. Epstein-Barr virus maintains lymphomas via its miRNAs. Oncogene. 33:1258-1264. http://dx.doi.org/10.1038/onc.2013.71
56. Verhoeven, R.J.A., S. Tong, G. Zhang, J. Zong, Y. Chen, D.-Y. Jin, M.-R. Chen, J. Pan, and H. Chen. 2016. NF-κB signaling regulates expression of Epstein-Barr virus BART microRNAs and long noncoding RNAs in nasopharyngeal carcinoma. J. Virol. 00613-16. http://dx.doi.org/10.1128/JVI.00613-16
57. Wen, W., D. Iwakiri, K. Yamamoto, S. Maruo, T. Kanda, and K. Takada. 2007. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. J. Virol. 81:1037-1042. http://dx.doi.org/10.1128/JVI.01416-06
58. Wiesner, M., C. Zentz, C. Mayr, R. Wimmer, W. Hammerschmidt, R. Zeidler, and A. Moosmann. 2008. Conditional immortalization of human B cells by CD40 ligation. PLoS One. 3:e1464. http://dx.doi.org/10.1371/journal.pone.0001464
59. Wu, Y., S. Maruo, M. Yajima, T. Kanda, and K. Takada. 2007. Epstein-Barr virus (EBV)-encoded RNA 2 (EBER2) but not EBER1 plays a critical role in EBV-induced B-cell growth transformation. J. Virol. 81:11236-11245. http://dx.doi.org/10.1128/JVI.00579-07
60. Xia, T., A. O'Hara, I. Araujo, J. Barreto, E. Carvalho, J.B. Sapucaia, J.C. Ramos, E. Luz, C. Pedroso, M. Manrique, et al. 2008. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res. 68:1436-1442. http://dx.doi.org/10.1158/0008-5472.CAN-07-5126
61. Zuo, J., A. Currin, B.D. Griffin, C. Shannon-Lowe, W.A. Thomas, M.E. Ressing, E.J.H.J. Wiertz, and M. Rowe. 2009. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog. 5:e1000255. http://dx.doi.org/10.1371/journal.ppat.1000255
62. Zuo, J., W.A. Thomas, T.A. Haigh, L. Fitzsimmons, H.M. Long, A.D. Hislop, G.S. Taylor, and M. Rowe. 2011. Epstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2. PLoS Pathog. 7:e1002455. http://dx.doi.org/10.1371/journal.ppat.1002455